id.exposure,id.outcome,outcome,exposure,method,nsnp,b,se,pval,lo_ci,up_ci,or,or_lci95,or_uci95,OR_CI,effect_direction,egger_intercept,egger_intercept_se,egger_intercept_pval,Q,Q_df,Q_pval,snp_r2.exposure,snp_r2.outcome,correct_causal_direction,steiger_pval,Fst,total_r2
met-c-900,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Free cholesterol in medium HDL,Inverse variance weighted,5,0.08552042097993577,0.03333939433577446,0.010313233686066863,0.02017520808181783,0.1508656338780537,1.0892838053596763,1.0203801032065294,1.162840401229086,1.09 [1.02:1.16],positive,0.0022095402034291774,0.010825833198482075,0.851337599458931,3.408170976422932,4,0.49197778543322046,0.01721655938880555,3.0409162041594735e-5,TRUE,1.7310387397132782e-70,76.6545636010931,0.017472102995130155
met-c-900,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Free cholesterol in medium HDL,MR Egger,5,0.06796648991579439,0.09296588329070538,0.5176503294641225,-0.11424664133398814,0.2501796211655769,1.0703294410481201,0.8920379153265715,1.2842560755447034,1.07 [0.89:1.28],overlaps null,0.0022095402034291774,0.010825833198482075,0.851337599458931,3.36149511059236,3,0.3391749700920495,0.01721655938880555,3.0409162041594735e-5,TRUE,1.7310387397132782e-70,76.6545636010931,0.017472102995130155
met-c-900,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Free cholesterol in medium HDL,Weighted median,5,0.07410503026939352,0.0389134429096728,0.05686389644458754,-0.0021653178335651613,0.1503753783723522,1.0769199087446142,0.9978370247759586,1.1622704520419105,1.08 [1:1.16],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-912,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total lipids in medium VLDL,Inverse variance weighted,12,-0.09786909966718466,0.02110021865026024,3.5129022323621696e-6,-0.1392255282216947,-0.05651267111267459,0.9067675921651758,0.8700317896080557,0.945054509527105,0.91 [0.87:0.95],negative,-0.005843483924100207,0.005697580154517617,0.32924571600934593,11.64453682434784,11,0.3909463557882379,0.04389236576333701,1.0887857970702431e-4,TRUE,4.3975639555098306e-160,75.16556497787158,0.04473699886764525
met-c-912,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total lipids in medium VLDL,MR Egger,12,-0.05121655408490308,0.050122450514124145,0.3309457781441679,-0.1494565570925864,0.04702344892278024,0.9500729060848968,0.8611758491897533,1.0481465866998692,0.95 [0.86:1.05],overlaps null,-0.005843483924100207,0.005697580154517617,0.32924571600934593,10.536257581588151,10,0.39476893079899755,0.04389236576333701,1.0887857970702431e-4,TRUE,4.3975639555098306e-160,75.16556497787158,0.04473699886764525
met-c-912,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total lipids in medium VLDL,Weighted median,12,-0.07977345123366718,0.028980478481970766,0.005911295795912195,-0.13657518905832988,-0.02297171340900448,0.9233255009470506,0.8723407273158874,0.9772901275884236,0.92 [0.87:0.98],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-914,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Phospholipids in medium VLDL,Inverse variance weighted,15,-0.08913727494344893,0.02294977480057779,1.027454657393478e-4,-0.13411883355258142,-0.04415571633431646,0.9147199968195432,0.874486140133884,0.9568049557119844,0.91 [0.87:0.96],negative,6.080872683005587e-5,0.0063320652345452986,0.9924836020588215,20.41983699597318,14,0.11745081728827755,0.049030248427037584,1.3432895893471833e-4,TRUE,8.833540734884542e-195,74.26165521183952,0.04986697899405863
met-c-914,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Phospholipids in medium VLDL,MR Egger,15,-0.08966038466267467,0.05945071229112838,0.15543011221085523,-0.2061837807532863,0.026863011427936956,0.9142416230307346,0.8136835231700249,1.0272270747544898,0.91 [0.81:1.03],overlaps null,6.080872683005587e-5,0.0063320652345452986,0.9924836020588215,20.41969213650115,13,0.08522812773035217,0.049030248427037584,1.3432895893471833e-4,TRUE,8.833540734884542e-195,74.26165521183952,0.04986697899405863
met-c-914,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Phospholipids in medium VLDL,Weighted median,15,-0.07761111979487245,0.027403448480093524,0.004623381458953937,-0.13132187881585577,-0.023900360773889143,0.9253241968487104,0.8769354620101998,0.9763829909569239,0.93 [0.88:0.98],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-890,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of large VLDL particles,Inverse variance weighted,10,-0.10506752701630674,0.022519724994482637,3.0775115566202265e-6,-0.1492061880054927,-0.060928866027120776,0.9002637284101953,0.861391487994461,0.9408901666511912,0.9 [0.86:0.94],negative,-0.0019499478233637915,0.0068451391160539304,0.7829820817674862,9.189945038801458,9,0.4199287044198096,0.03540349442168227,9.84953788396345e-5,TRUE,4.574641452185839e-126,71.65232430338632,0.03643550360591996
met-c-890,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of large VLDL particles,MR Egger,10,-0.08889590505674475,0.06154303069974924,0.18661144201256422,-0.20952024522825324,0.03172843511476377,0.9149408093292148,0.81097322092892965,1.0322371478766252,0.91 [0.81:1.03],overlaps null,-0.0019499478233637915,0.0068451391160539304,0.7829820817674862,9.09766213729759,8,0.3341244460124889,0.03540349442168227,9.84953788396345e-5,TRUE,4.574641452185839e-126,71.65232430338632,0.03643550360591996
met-c-890,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of large VLDL particles,Weighted median,10,-0.09079180435187297,0.02942330451139298,0.0020306632116608107,-0.14846148119420322,-0.03312212750954272,0.9132078170022829,0.862033211020854,0.9674204037295502,0.91 [0.86:0.97],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-887,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Inverse variance weighted,12,-0.1108036839253861,0.021033107321318446,1.3787259865239992e-7,-0.15202857427517025,-0.06957879357560195,0.8951144570378394,0.8589637361242956,0.9327866328948313,0.9 [0.86:0.93],negative,-0.0017164075940272916,0.005997785760562073,0.7805860480652702,9.259006785997178,11,0.5979982883089735,0.04154318433727714,1.1889190639346523e-4,TRUE,5.2748315161173836e-148,69.97993272180987,0.04244046154729363
met-c-887,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,MR Egger,12,-0.09713283372848162,0.05219653293391849,0.09237753320042107,-0.19943803827896187,0.0051723708219986175,0.9074354600916394,0.8191909777232537,1.0051857706249139,0.91 [0.82:1.01],overlaps null,-0.0017164075940272916,0.005997785760562073,0.7805860480652702,9.17711148997372,10,0.5153817095246411,0.04154318433727714,1.1889190639346523e-4,TRUE,5.2748315161173836e-148,69.97993272180987,0.04244046154729363
met-c-887,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Weighted median,12,-0.10175410886741111,0.02767232590364509,2.3589392221077147e-4,-0.1559918676385555,-0.047516350096266737,0.9032516259300248,0.8555661481158832,0.9535948816370512,0.9 [0.86:0.95],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-a-444,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),X-10510,Inverse variance weighted,3,0.33647165976786253,0.16608469104451587,0.04277461102500826,0.01094566532061142,0.6619976542151136,1.3999991924055424,1.0110057882769519,1.938661243548939,1.4 [1.01:1.94],positive,-0.01224103750109498,0.010529460766948317,0.45223739129465773,1.375279733627996,2,0.5027612534383014,0.02936301983243819,1.603527175883995e-5,TRUE,9.617328702133543e-49,76.50832914696583,0.028627910458706194
met-a-444,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),X-10510,MR Egger,3,0.7235552013013743,0.3720843514688007,0.3023805372830422,-0.0057301275774750415,1.4528405301802236,2.0617501331272976,0.9942862582909073,4.2752412356147955,2.06 [0.99:4.28],overlaps null,-0.01224103750109498,0.010529460766948317,0.45223739129465773,0.02375438555315944,1,0.8775115093514134,0.02936301983243819,1.603527175883995e-5,TRUE,9.617328702133543e-49,76.50832914696583,0.028627910458706194
met-a-444,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),X-10510,Weighted median,3,0.3615584901595058,0.17880903099163348,0.043172521746193813,0.011092789415904192,0.7120241909031074,1.435564985953775,1.0111545425312871,2.038112615048352,1.44 [1.01:2.04],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-a-14,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Snoring,Inverse variance weighted,20,1.145291789536713,0.4729016791927548,0.015442185030263978,0.21840449831891362,2.072179080754512,3.1433584221353486,1.2440901982482233,7.942110776149537,3.14 [1.24:7.94],positive,0.012905288683445261,0.019316310263367237,0.5125443344947298,110.28420849990157,19,7.066016315157208e-15,0.0025201064469917724,4.3290328632158943e-4,TRUE,8.807644445930747e-27,37.82819614300019,0.0025201085296365404
ukb-a-14,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Snoring,MR Egger,20,-0.3468195765001512,2.28434255992699,0.8810139562233066,-4.824130993957052,4.130491840956749,0.7069328640536668,0.008033532025803043,62.208512105752604,0.71 [0.01:62.21],overlaps null,0.012905288683445261,0.019316310263367237,0.5125443344947298,107.61557023544376,18,8.7326819667107e-15,0.0025201064469917724,4.3290328632158943e-4,TRUE,8.807644445930747e-27,37.82819614300019,0.0025201085296365404
ukb-a-14,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Snoring,Weighted median,20,0.7746865197875095,0.3329490553199063,0.019979005998672975,0.12210637136049307,1.4272666682145259,2.1699117961429137,1.1298742816528826,4.167293016132838,2.17 [1.13:4.17],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-950,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of very large VLDL particles,Inverse variance weighted,8,-0.11547561924641662,0.02690260567379411,1.7678547368332804e-5,-0.16820472636705308,-0.06274651212578017,0.8909422938168053,0.8451807861796097,0.9391815146432644,0.89 [0.85:0.94],negative,-0.00552360605213843,0.010339315328770086,0.6123852943368006,7.702366374063004,7,0.3595690374644298,0.025069206432647134,8.964328672164691e-5,TRUE,6.726342535192916e-88,61.85752287548454,0.025448099407625865
met-c-950,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of very large VLDL particles,MR Egger,8,-0.07126551986928509,0.0874889050968957,0.44643823186859566,-0.24274377385920068,0.1002127341206305,0.9312146033192492,0.7844724903815,1.1054060506485246,0.93 [0.78:1.11],overlaps null,-0.00552360605213843,0.010339315328770086,0.6123852943368006,7.352620397897782,6,0.2894640406912669,0.025069206432647134,8.964328672164691e-5,TRUE,6.726342535192916e-88,61.85752287548454,0.025448099407625865
met-c-950,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of very large VLDL particles,Weighted median,8,-0.09762614610930995,0.03409723452158965,0.004194267378805129,-0.16445672577162568,-0.03079556644699423,0.9069879213416526,0.8483544680350038,0.9696737866720467,0.91 [0.85:0.97],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-945,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total lipids in very large HDL,Inverse variance weighted,13,0.04598951191807146,0.016406163389104632,0.005060062717883253,0.013833431675426382,0.07814559216071654,1.0470634292123187,1.0139295563245374,1.081280073112835,1.05 [1.01:1.08],positive,0.0024294720155723835,0.006400612683468191,0.7114912890211234,10.999227464288456,12,0.5289848942627584,0.07188097537276782,5.77221034971315e-5,TRUE,5.5116410737368173e-278,115.1596956433831,0.07212712269102604
met-c-945,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total lipids in very large HDL,MR Egger,13,0.02899476939950346,0.04768498671418104,0.5555018152142098,-0.06446780456029137,0.1224573433592983,1.0294192099804178,0.9375662991353961,1.1302709054857714,1.03 [0.94:1.13],overlaps null,0.0024294720155723835,0.006400612683468191,0.7114912890211234,10.85515509234918,11,0.45547661588646815,0.07188097537276782,5.77221034971315e-5,TRUE,5.5116410737368173e-278,115.1596956433831,0.07212712269102604
met-c-945,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total lipids in very large HDL,Weighted median,13,0.037950267348703715,0.0223554017491118,0.08958550191104626,-0.005866320079555412,0.08176685477696284,1.0386795753048472,0.9941508531783964,1.0852027704912721,1.04 [0.99:1.09],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-923,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Triglycerides in small HDL,Inverse variance weighted,11,-0.10918217038586582,0.023960922933925898,5.196941283997699e-6,-0.15614557933636058,-0.06221876143537106,0.8965670746506287,0.8554346476975069,0.9396772991498374,0.9 [0.86:0.94],negative,-0.007166037971781275,0.008092983278626623,0.39894651024796324,11.689766112023198,10,0.3063557184557254,0.040816500426747795,1.2494629936453427e-4,TRUE,1.0277474163359103e-162,77.97410997797596,0.04162191409826003
met-c-923,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Triglycerides in small HDL,MR Egger,11,-0.05166857639472079,0.06932320229279798,0.47508658986769225,-0.18754205288860482,0.08420490009916325,0.9496435489821984,0.8289942558442794,1.087851771910113,0.95 [0.83:1.09],overlaps null,-0.007166037971781275,0.008092983278626623,0.39894651024796324,10.753006172846582,9,0.2930198159909154,0.040816500426747795,1.2494629936453427e-4,TRUE,1.0277474163359103e-162,77.97410997797596,0.04162191409826003
met-c-923,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Triglycerides in small HDL,Weighted median,11,-0.08740100710373486,0.02910024737412081,0.002669413527226185,-0.14443749195701164,-0.03036452225045807,0.9163095753000295,0.8655090119867878,0.9700918490255276,0.92 [0.87:0.97],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-913,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of medium VLDL particles,Inverse variance weighted,14,-0.09827323038703331,0.020986977030868794,2.8328449745955155e-6,-0.13940770536753616,-0.057138755406530475,0.9064012135628292,0.8698733041364873,0.944463010925166,0.91 [0.87:0.94],negative,-0.0032782714988659387,0.00570928035409295,0.5764374476535855,14.685771775552018,13,0.32737790227242197,0.04631234303943318,1.2338130614094215e-4,TRUE,1.8217962334698038e-168,68.54879385328462,0.047467511907138535
met-c-913,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of medium VLDL particles,MR Egger,14,-0.07065679515574919,0.05270266785738129,0.20485661945676173,-0.17395402415621652,0.03264043384471814,0.9317816292257274,0.8403355319054442,1.033178976252362,0.93 [0.84:1.03],overlaps null,-0.0032782714988659387,0.00570928035409295,0.5764374476535855,14.293062513691954,12,0.28238668526860783,0.04631234303943318,1.2338130614094215e-4,TRUE,1.8217962334698038e-168,68.54879385328462,0.047467511907138535
met-c-913,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of medium VLDL particles,Weighted median,14,-0.08477900757510148,0.028299055667761752,0.002737038057012382,-0.14024515668391452,-0.02931285846628845,0.9187152910891302,0.8691451325395442,0.9711125961377727,0.92 [0.87:0.97],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-911,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Free cholesterol in medium VLDL,Inverse variance weighted,12,-0.0820990882075491,0.025983377489747713,0.0015794396481323076,-0.13302650808745461,-0.031171668327643585,0.9211806760318887,0.8754418855111287,0.969309159110117,0.92 [0.88:0.97],negative,0.0021133974574535906,0.007346832635410454,0.7794794964989283,18.653204848049665,11,0.06760980610091803,0.04474894373069453,1.1093092768413383e-4,TRUE,2.472301964986893e-178,84.29699099777352,0.04548692518487639
met-c-911,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Free cholesterol in medium VLDL,MR Egger,12,-0.10006025941536209,0.06808187461591146,0.17238826992884584,-0.23350073366254856,0.03338021483182438,0.9047828947049396,0.791757014857565,1.033943585201982,0.9 [0.79:1.03],overlaps null,0.0021133974574535906,0.007346832635410454,0.7794794964989283,18.500118459601968,10,0.047090986367484856,0.04474894373069453,1.1093092768413383e-4,TRUE,2.472301964986893e-178,84.29699099777352,0.04548692518487639
met-c-911,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Free cholesterol in medium VLDL,Weighted median,12,-0.07699853011675968,0.027398173459452915,0.004948723929532144,-0.13069895009728738,-0.023298110136231967,0.9258912145574738,0.8774819004722525,0.9769711953412793,0.93 [0.88:0.98],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-909,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in medium VLDL,Inverse variance weighted,15,-0.07499743410633265,0.026003753647244016,0.003925336888315574,-0.12596479125493093,-0.024030076957734382,0.9277458668227434,0.8816458878822614,0.9762563464954612,0.93 [0.88:0.98],negative,0.0014632674487147577,0.008255760150259157,0.8620500460777623,26.752788688964877,14,0.020728282229680928,0.05159615812528017,1.5011015928241415e-4,TRUE,2.7560098744288703e-207,79.54302804071806,0.05249638272416103
met-c-909,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in medium VLDL,MR Egger,15,-0.08691703832228659,0.07245051877690378,0.2516739507806798,-0.228920055125018,0.05508597848044483,0.9167531478575939,0.7953921184868875,1.0566314583373164,0.92 [0.8:1.06],overlaps null,0.0014632674487147577,0.008255760150259157,0.8620500460777623,26.688295955944195,13,0.01372197308568142,0.05159615812528017,1.5011015928241415e-4,TRUE,2.7560098744288703e-207,79.54302804071806,0.05249638272416103
met-c-909,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in medium VLDL,Weighted median,15,-0.07600134125053522,0.026445419392607188,0.0040544457117865735,-0.1278343632600453,-0.02416831924102513,0.9268149634674828,0.8799991272602916,0.9761213959171976,0.93 [0.88:0.98],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-909,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in medium VLDL,Inverse variance weighted,15,-0.08677884385983368,0.02565408625204566,7.178956176853554e-4,-0.13706085291384318,-0.03649683480582419,0.91687984682041,0.8719171658175185,0.964161145648737,0.92 [0.87:0.96],negative,0.00706158958955181,0.007913680757125957,0.3884368071934581,18.3959340511355,14,0.1893382828703807,0.05159615812528017,1.682922002595481e-4,TRUE,9.926862493824856e-201,79.54302804071806,0.05249638272416103
met-c-909,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in medium VLDL,MR Egger,15,-0.1443103293228145,0.06946000037438936,0.05812475189655003,-0.2804519300566176,-0.008168728589011381,0.8656190793907556,0.7554422572359621,0.991864544812267,0.87 [0.76:0.99],negative,0.00706158958955181,0.007913680757125957,0.3884368071934581,17.334217050542822,13,0.1844725517823226,0.05159615812528017,1.682922002595481e-4,TRUE,9.926862493824856e-201,79.54302804071806,0.05249638272416103
met-c-909,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in medium VLDL,Weighted median,15,-0.10964135850933875,0.03236362966109286,7.04567785864265e-4,-0.17307407264508073,-0.046208644373596744,0.8961554762058432,0.8410753118641165,0.9548427188449791,0.9 [0.84:0.95],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-900,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Free cholesterol in medium HDL,Inverse variance weighted,5,0.11669574610345133,0.03952141376631666,0.0031498553598640964,0.03923377512147068,0.194157717085432,1.1237774639987026,1.040013584535637,1.2142877817843363,1.12 [1.04:1.21],positive,0.010080578928850685,0.012157559349749377,0.4678242268567305,3.228729197548505,4,0.5203032241233286,0.01721655938880555,5.29720951409406e-5,TRUE,6.996510859363184e-67,76.6545636010931,0.017472102995130155
met-c-900,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Free cholesterol in medium HDL,MR Egger,5,0.03682892044723237,0.10411507636804955,0.7469385187522444,-0.16723662923414473,0.24089447012860948,1.0375155079650864,0.8459993994601498,1.2723867534125315,1.04 [0.85:1.27],overlaps null,0.010080578928850685,0.012157559349749377,0.4678242268567305,2.5412205705946196,3,0.4678876405356666,0.01721655938880555,5.29720951409406e-5,TRUE,6.996510859363184e-67,76.6545636010931,0.017472102995130155
met-c-900,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Free cholesterol in medium HDL,Weighted median,5,0.09410323523355575,0.046784682079854055,0.0442820374526972,0.0024052583570418062,0.1858012121100697,1.0986731618432775,1.0024081533114964,1.2041828596136788,1.1 [1:1.2],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-912,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total lipids in medium VLDL,Inverse variance weighted,12,-0.11445934418932477,0.024417679938437607,2.7648141153228274e-6,-0.16231799686866247,-0.06660069150998707,0.8918481964924971,0.8501708098948115,0.9355687072875755,0.89 [0.85:0.94],negative,-0.0025314341577620278,0.006613469124851423,0.7099007940917269,6.99897145548589,11,0.7991667888352807,0.04389236576333701,1.276929016254188e-4,TRUE,4.123078313103511e-155,75.16556497787158,0.04473699886764525
met-c-912,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total lipids in medium VLDL,MR Egger,12,-0.09426061943347849,0.05814542321906888,0.13605908284793825,-0.2082256489428535,0.019704410075896517,0.9100455557746165,0.8120237837289253,1.0198998233549275,0.91 [0.81:1.02],overlaps null,-0.0025314341577620278,0.006613469124851423,0.7099007940917269,6.852458978369084,10,0.7392964586429625,0.04389236576333701,1.276929016254188e-4,TRUE,4.123078313103511e-155,75.16556497787158,0.04473699886764525
met-c-912,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total lipids in medium VLDL,Weighted median,12,-0.1105312698016938,0.03268309135690327,7.198375371983069e-4,-0.17459012886122421,-0.04647241074216339,0.8953583320742518,0.8398011604959164,0.9545908966610486,0.9 [0.84:0.95],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-914,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Phospholipids in medium VLDL,Inverse variance weighted,15,-0.10670024010894345,0.023124976924004968,3.948611623378793e-6,-0.1520251948799932,-0.061375285337893715,0.8987950553211446,0.8589666389071074,0.9404702288526271,0.9 [0.86:0.94],negative,0.0043590072834940015,0.006263388560572522,0.49871392218961674,14.633731180302394,14,0.4036411609036043,0.049030248427037584,1.6408940334773853e-4,TRUE,8.815609586818571e-188,74.26165521183952,0.04986697899405863
met-c-914,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Phospholipids in medium VLDL,MR Egger,15,-0.1442039428575533,0.058814814026673996,0.029112676871059118,-0.25948097834983436,-0.028926907365272272,0.8657111744436213,0.7714518821422399,0.9714874704503862,0.87 [0.77:0.97],negative,0.0043590072834940015,0.006263388560572522,0.49871392218961674,14.108099373058561,13,0.36627537926345677,0.049030248427037584,1.6408940334773853e-4,TRUE,8.815609586818571e-188,74.26165521183952,0.04986697899405863
met-c-914,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Phospholipids in medium VLDL,Weighted median,15,-0.11003332657056042,0.031208468980476616,4.222819711058068e-4,-0.1712019257722946,-0.04886472736882625,0.895804280714486,0.8426514032559445,0.9523099424574971,0.9 [0.84:0.95],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-886,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in large VLDL,Inverse variance weighted,10,-0.12704895722217777,0.027009031955249025,2.5518403647291545e-6,-0.17998665985446585,-0.07411125458988968,0.8806905553785264,0.8352813541117751,0.9285683805999895,0.88 [0.84:0.93],negative,0.002715773869637891,0.009072389611631065,0.7723062876261101,3.4781589042469956,9,0.9422947836858364,0.03637281900350595,1.235787075375985e-4,TRUE,2.1080729323056317e-138,73.86688913694599,0.03687388355790334
met-c-886,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in large VLDL,MR Egger,10,-0.14964163628946006,0.08016091253887898,0.09889735416004168,-0.30675702486566286,0.007473752286742741,0.8610164782038002,0.7358293674278641,1.0075017504804227,0.86 [0.74:1.01],overlaps null,0.002715773869637891,0.009072389611631065,0.7723062876261101,3.388551514727487,8,0.9076649642554027,0.03637281900350595,1.235787075375985e-4,TRUE,2.1080729323056317e-138,73.86688913694599,0.03687388355790334
met-c-886,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in large VLDL,Weighted median,10,-0.12157493890969891,0.03625550968491427,7.985936827756994e-4,-0.19263573789213087,-0.05051413992726694,0.8855246906074971,0.8247823563865221,0.950740485175972,0.89 [0.82:0.95],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-890,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of large VLDL particles,Inverse variance weighted,10,-0.12646981816478128,0.02655322153662789,1.908489744448696e-6,-0.17851413237657193,-0.07442550395299062,0.8812007453978499,0.8365122348879458,0.9282766244222876,0.88 [0.84:0.93],negative,0.0017686593639060467,0.0076430907585983004,0.8228081018542107,3.5273625192690714,9,0.9396853995391118,0.03540349442168227,1.1476806091084071e-4,TRUE,3.494186102350037e-122,71.65232430338632,0.03643550360591996
met-c-890,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of large VLDL particles,MR Egger,10,-0.14112289705271303,0.06866390849724356,0.07390087652083754,-0.2757041577073104,-0.006541636398115641,0.8683825834793736,0.7590374529283391,0.9934797135254205,0.87 [0.76:0.99],negative,0.0017686593639060467,0.0076430907585983004,0.8228081018542107,3.473813642929679,8,0.9012124421193266,0.03540349442168227,1.1476806091084071e-4,TRUE,3.494186102350037e-122,71.65232430338632,0.03643550360591996
met-c-890,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of large VLDL particles,Weighted median,10,-0.1236804286963851,0.03479900690424861,3.792219993979087e-4,-0.19188648222871235,-0.05547437516405783,0.8836621888428389,0.8254005608057927,0.9460362653839341,0.88 [0.83:0.95],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-887,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Inverse variance weighted,12,-0.12180690324873716,0.025032526101641757,1.1391101034892839e-6,-0.170870654407955,-0.07274315208951931,0.885319304280011,0.8429305957776543,0.9298396267224694,0.89 [0.84:0.93],negative,-0.0010479321001567515,0.007138805503633032,0.8862120451026464,3.8628541231082787,11,0.9737583467259494,0.04154318433727714,1.2167667676605435e-4,TRUE,1.7051187970776087e-144,69.97993272180987,0.04244046154729363
met-c-887,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,MR Egger,12,-0.11346174110286883,0.062116833394283165,0.09771968676570765,-0.23521073455566383,0.008287252349926166,0.8927383509425573,0.7904042665850366,1.0083216866819535,0.89 [0.79:1.01],overlaps null,-0.0010479321001567515,0.007138805503633032,0.8862120451026464,3.841305715200386,10,0.9542220892176624,0.04154318433727714,1.2167667676605435e-4,TRUE,1.7051187970776087e-144,69.97993272180987,0.04244046154729363
met-c-887,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Weighted median,12,-0.12181783705758127,0.032711586089980364,1.960935273655086e-4,-0.18593254579394278,-0.057703128321219765,0.885309624420891,0.8303296023170365,0.9439301319682433,0.89 [0.83:0.94],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-864,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in HDL,Inverse variance weighted,12,0.05999628415924076,0.023417591021135848,0.010406599591494405,0.014097805757814504,0.10589476256066702,1.061832600937171,1.0141976484573414,1.1117048773757054,1.06 [1.01:1.11],positive,0.003945900598740118,0.007999784030541336,0.6324871620435073,10.932232347055283,11,0.4489580220880055,0.046906112524312066,7.814668862293916e-5,TRUE,3.0079076505215615e-188,89.64046760115828,0.047559490820783715
met-c-864,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in HDL,MR Egger,12,0.03278721628590523,0.06023448848562157,0.5981439174199733,-0.08527238114591304,0.15084681371772352,1.0333306399151885,0.9182621330427003,1.1628185165922333,1.03 [0.92:1.16],overlaps null,0.003945900598740118,0.007999784030541336,0.6324871620435073,10.672572457313901,10,0.38358994143897934,0.046906112524312066,7.814668862293916e-5,TRUE,3.0079076505215615e-188,89.64046760115828,0.047559490820783715
met-c-864,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in HDL,Weighted median,12,0.05753865421210337,0.03132608209126391,0.06624458056392261,-0.0038604666867738946,0.11893777511098064,1.059226213418141,0.9961469753351068,1.126299832225764,1.06 [1:1.13],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-a-14,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Snoring,Inverse variance weighted,20,1.0290833563048423,0.4758410664725733,0.030567191687104724,0.09643486601859863,1.961731846591086,2.7984994317802063,1.1012378508020857,7.111632663161733,2.8 [1.1:7.11],positive,0.009065257607774355,0.01962087739866445,0.6496016006457482,78.65509170168284,19,3.1677111690193667e-9,0.0025201064469917724,4.1622129984000334e-4,TRUE,1.3273909746945803e-23,37.82819614300019,0.0025201085296365404
ukb-a-14,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Snoring,MR Egger,20,-0.019829905487491306,2.3217098598036174,0.9932792396419923,-4.570381230702582,4.530721419727598,0.9803654139026813,0.01035401169795421,92.82550308171625,0.98 [0.01:92.83],overlaps null,0.009065257607774355,0.01962087739866445,0.6496016006457482,77.73324701726051,18,2.129367826385277e-9,0.0025201064469917724,4.1622129984000334e-4,TRUE,1.3273909746945803e-23,37.82819614300019,0.0025201085296365404
ukb-a-14,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Snoring,Weighted median,20,1.000552666137717,0.37175625900651993,0.0071148310242231585,0.27191039848493803,1.7291949337904962,2.7197845459907044,1.3124693967959902,5.636114636019726,2.72 [1.31:5.64],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-950,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of very large VLDL particles,Inverse variance weighted,8,-0.1391135720800407,0.03054059008982566,5.237591602806355e-6,-0.19897312865609898,-0.0792540155039824,0.8701292004631066,0.8195719160358419,0.9238052337867739,0.87 [0.82:0.92],negative,0.0010403735339451178,0.01110644928448246,0.9284187048588701,3.7705434617636913,7,0.8057944870832001,0.025069206432647134,1.0847540964976082e-4,TRUE,6.961976443311505e-85,61.85752287548454,0.025448099407625865
met-c-950,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of very large VLDL particles,MR Egger,8,-0.1474471708351918,0.09406101746894645,0.16802695798173464,-0.3318067650743268,0.03691242340394324,0.8629080238274478,0.7176259798602032,1.0376021471949004,0.86 [0.72:1.04],overlaps null,0.0010403735339451178,0.01110644928448246,0.9284187048588701,3.7617688458453777,6,0.7088782417193344,0.025069206432647134,1.0847540964976082e-4,TRUE,6.961976443311505e-85,61.85752287548454,0.025448099407625865
met-c-950,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of very large VLDL particles,Weighted median,8,-0.1257316760997071,0.039081096234873484,0.001294486348554988,-0.20233062472005914,-0.04913272747935506,0.8818514368576273,0.8168248208149312,0.9520547574839888,0.88 [0.82:0.95],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-923,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Triglycerides in small HDL,Inverse variance weighted,11,-0.12681078099445475,0.026375200898970833,1.5248202051290666e-6,-0.1785061747564376,-0.07511538723247192,0.8809003399146508,0.8365188915610344,0.9276364427510715,0.88 [0.84:0.93],negative,-0.004922416152599932,0.008784249839620468,0.5889031600750094,7.493601928752925,10,0.6781674796420547,0.040816500426747795,1.4774312449534457e-4,TRUE,4.938597245775271e-157,77.97410997797596,0.04162191409826003
met-c-923,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Triglycerides in small HDL,MR Egger,11,-0.08727435267118043,0.07532308609844134,0.2764111790390633,-0.23490760142412542,0.060358896081764576,0.9164256373190628,0.7906439006242212,1.0622177039152412,0.92 [0.79:1.06],overlaps null,-0.004922416152599932,0.008784249839620468,0.5889031600750094,7.179589169115411,9,0.618427709711165,0.040816500426747795,1.4774312449534457e-4,TRUE,4.938597245775271e-157,77.97410997797596,0.04162191409826003
met-c-923,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Triglycerides in small HDL,Weighted median,11,-0.11574537914351934,0.034689886289541394,8.481778846392646e-4,-0.18373755627102048,-0.04775320201601821,0.8907019857295007,0.832154168814307,0.9533690476043382,0.89 [0.83:0.95],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-927,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in small VLDL,Inverse variance weighted,16,-0.07309572499407573,0.025738730921479377,0.004512601248719013,-0.12354363760017531,-0.022647812387976148,0.9295118482508036,0.8837830742301636,0.9776067241287939,0.93 [0.88:0.98],negative,0.0048752888860596946,0.00819835316166458,0.5615545782002507,17.73526531527044,15,0.27683913014450523,0.05106512624201757,1.2150266626966356e-4,TRUE,4.401304566060291e-202,74.10953558607433,0.05217660298629597
met-c-927,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in small VLDL,MR Egger,16,-0.11115923678940622,0.06920516952624252,0.1305367655712348,-0.24680136906084155,0.02448289548202913,0.8947962531015264,0.781295867651628,1.0247850625027721,0.89 [0.78:1.02],overlaps null,0.0048752888860596946,0.00819835316166458,0.5615545782002507,17.298323661650755,14,0.2406284879698101,0.05106512624201757,1.2150266626966356e-4,TRUE,4.401304566060291e-202,74.10953558607433,0.05217660298629597
met-c-927,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total cholesterol in small VLDL,Weighted median,16,-0.11880429567237741,0.03528197378036991,7.591348328344318e-4,-0.18795696428190242,-0.049651627062852394,0.8879815655933664,0.8286503680289711,0.9515608648182949,0.89 [0.83:0.95],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-913,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of medium VLDL particles,Inverse variance weighted,14,-0.11035454073457089,0.02355048317663528,2.7877097407829377e-6,-0.15651348776077603,-0.06419559370836575,0.89551658190028,0.8551199839713493,0.9378215495958171,0.9 [0.86:0.94],negative,4.4079964563414615e-4,0.006301420748745654,0.9453837498500796,12.250183253709059,13,0.5072433306924957,0.04631234303943318,1.4987887879969308e-4,TRUE,7.590851689479444e-163,68.54879385328462,0.047467511907138535
met-c-913,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of medium VLDL particles,MR Egger,14,-0.11406153282325966,0.058088043447828246,0.07317150853560525,-0.22791409798100304,-2.089676655162992e-4,0.8922030544204453,0.796192651454193,0.9997910541667056,0.89 [0.8:1],negative,4.4079964563414615e-4,0.006301420748745654,0.9453837498500796,12.245189929147024,12,0.4261945406159357,0.04631234303943318,1.4987887879969308e-4,TRUE,7.590851689479444e-163,68.54879385328462,0.047467511907138535
met-c-913,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Concentration of medium VLDL particles,Weighted median,14,-0.11440293136978946,0.033346590758062636,6.019739273668222e-4,-0.17976224925559223,-0.0490436134839867,0.8918985095829971,0.8354688211346859,0.9521396026676281,0.89 [0.84:0.95],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-911,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Free cholesterol in medium VLDL,Inverse variance weighted,12,-0.09803225220913797,0.02568532701648649,1.352684059889097e-4,-0.1483754931614515,-0.047689011256824454,0.9066196627954076,0.8621073387478393,0.9534302470514942,0.91 [0.86:0.95],negative,0.007080172376910828,0.006938921310800361,0.331609810186261,12.857866741374433,11,0.30271663983712205,0.04474894373069453,1.3002146158480078e-4,TRUE,1.993365712314008e-172,84.29699099777352,0.04548692518487639
met-c-911,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Free cholesterol in medium VLDL,MR Egger,12,-0.1581984893165408,0.06429818617493616,0.03365410043291088,-0.2842229342194157,-0.03217404441366592,0.8536803187277081,0.752598845966592,0.9683380335868752,0.85 [0.75:0.97],negative,0.007080172376910828,0.006938921310800361,0.331609810186261,11.645429549336566,10,0.3094871272032251,0.04474894373069453,1.3002146158480078e-4,TRUE,1.993365712314008e-172,84.29699099777352,0.04548692518487639
met-c-911,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Free cholesterol in medium VLDL,Weighted median,12,-0.107295916676635,0.03150190460651047,6.591888647534157e-4,-0.16903964970539553,-0.04555218364787448,0.8982598235958577,0.8444754195206282,0.9554697413744576,0.9 [0.84:0.96],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-a-495,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),X-11315,Inverse variance weighted,3,-0.6630818030981676,0.32602030566688683,0.04196504965277294,-1.3020816022052657,-0.02408200399106941,0.5152609523288315,0.27196508029250793,0.9762056537157875,0.52 [0.27:0.98],negative,0.04350353546808009,0.03669935412205591,0.4461200353967614,1.4219591915918248,2,0.4911628206878737,0.01755136770244782,6.443752101838354e-5,TRUE,7.744617981569097e-27,46.37255676734271,0.01756510144081268
met-a-495,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),X-11315,MR Egger,3,-1.8714957036554485,1.07027533614746,0.3307164065337876,-3.96923536250447,0.22624395519357288,0.15389331080213325,0.01888786998857233,1.2538815188780383,0.15 [0.02:1.25],overlaps null,0.04350353546808009,0.03669935412205591,0.4461200353967614,0.016778208979302652,1,0.8969377139042827,0.01755136770244782,6.443752101838354e-5,TRUE,7.744617981569097e-27,46.37255676734271,0.01756510144081268
met-a-495,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),X-11315,Weighted median,3,-0.5202397783812066,0.38932955280737996,0.18146911459847223,-1.2833257018836712,0.24284614512125813,0.5943780118848268,0.27711416716325027,1.2748724636804154,0.59 [0.28:1.27],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-a-14,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Snoring,Inverse variance weighted,20,1.7622048864466424,0.5719243196836523,0.0020617819844558167,0.6412332198666839,2.883176553026601,5.825267297877867,1.898821099908777,17.870951135604905,5.83 [1.9:17.87],positive,0.017946944651889833,0.023428787419590126,0.453592729015176,48.50988383160177,19,2.1641596098964213e-4,0.0025201064469917724,7.373194462980571e-4,TRUE,3.624226366763784e-12,37.82819614300019,0.0025201085296365404
ukb-a-14,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Snoring,MR Egger,20,-0.3177297856937,2.7761346057272407,0.9101477346072585,-5.7589536129190915,5.123494041531691,0.727799423662961,0.0031544106066303127,167.9210689853657,0.73 [0:167.92],overlaps null,0.017946944651889833,0.023428787419590126,0.453592729015176,46.9784180197869,18,2.1323823659755343e-4,0.0025201064469917724,7.373194462980571e-4,TRUE,3.624226366763784e-12,37.82819614300019,0.0025201085296365404
ukb-a-14,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Snoring,Weighted median,20,1.450260947930266,0.5237240336758598,0.005620586948719491,0.42376184192558064,2.4767600539349512,4.264227111236544,1.5276977169091153,11.902637972775432,4.26 [1.53:11.9],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
